Dixon Technologies Acquires 51% Stake in Adivistar Electronics for Rs 2.55 Crore

TECHNOLOGY
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Dixon Technologies Acquires 51% Stake in Adivistar Electronics for Rs 2.55 Crore

Dixon Technologies (India) Ltd has acquired a 51% majority stake in Adivistar Electronics India Private Limited for Rs 2.55 crore. The newly formed entity, which focuses on Original Equipment Manufacturing (OEM) of electronic devices, aims to strengthen Dixon's position within India's Android smartphone ecosystem through a strategic partnership with vivo.

Dixon Technologies Expands Smartphone Manufacturing Capacity

Transaction Value: Rs 2.55 crore for a 51% equity stake in Adivistar Electronics India Private Limited.

Reader Takeaway: This acquisition scales Dixon's OEM smartphone capacity via a targeted partnership with vivo to grow Android market share.

What just happened

Dixon Technologies (India) Ltd has finalized a 51% stake acquisition in the newly incorporated Adivistar Electronics India Private Limited. The transaction involved a cash consideration of Rs 2.55 crore, with Dixon subscribing to 25,50,000 equity shares at a face value of Rs 10 per share. Adivistar, which was incorporated on August 13, 2026, is currently in the pre-operational phase but is positioned to function as an OEM for electronic devices.

Why this matters

The acquisition is a strategic move to deepen Dixon’s presence in the competitive Indian smartphone manufacturing market. By integrating Adivistar, Dixon gains an additional production arm specifically aimed at the Android smartphone segment. A key highlight of this filing is the explicitly mentioned partnership with vivo, which is expected to utilize this facility to drive production volumes. For shareholders, this represents a tactical expansion of the company's production infrastructure.

What changes now

Following the subscription completion on September 21, 2026, Adivistar is now a subsidiary of Dixon Technologies. The entity will now shift its focus from incorporation to setting up its manufacturing lines. All regulatory and governmental approvals required for the acquisition have been secured, clearing the path for operational scaling.

What to track next

Investors should look for updates regarding the commencement of commercial production at Adivistar’s facilities. The timeline for revenue contribution from this new unit and the extent of the manufacturing ramp-up under the vivo partnership will be critical indicators for assessing the impact on Dixon’s overall margins and top-line growth in the coming quarters.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.